ACA vs BIO · P/E 57, rev $2.88B vs rev $2.58B
Arcosa Inc (ACA) versus BIO (BIO) — a side-by-side from cached financials, not a winner call.
Arcosa Inc (ACA) is a engineering & construction company listed on US.
BIO (BIO) common stock.
Latest reported ACA revenue for 2025-12-31 was $2.88B. Net income was $208.4M. Revenue was up 12.2% from 2024-12-31 to 2025-12-31. ACA currently screens at market cap $4.39B and trailing P/E 56.6.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
ACA currently screens at market cap $4.39B and trailing P/E 56.6. BIO currently screens at market cap $0.
Not investment advice. Open the ACA and BIO stock pages for the full models.
Not investment advice.